Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | FLT1 | P17948 | 6/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | HLA-A | P04439 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229449 | 0.92 | TGFBR1 (0.56) | TGFBR1PRKD1KDRSYKEGFR | |
| SCHEMBL2200375 | 0.86 | MAPT (0.50) | TGFBR1PRKD1KDRFLT1SYK | |
| SCHEMBL2203187 | 0.86 | NPC1 (0.46) | TGFBR1PRKD1MEN1NPC1RAB9A | |
| SCHEMBL4035715 | 0.83 | IKBKB (0.44) | TGFBR1PRKD1MEN1NPC1RAB9A | |
| SCHEMBL2202465 | 0.82 | EGFR (0.61) | TGFBR1PRKD1KDREGFR | |
| SCHEMBL2198086 | 0.81 | TGFBR1 (0.52) | TGFBR1PRKD1MEN1NPC1RAB9A | |
| SCHEMBL2202398 | 0.80 | IKBKB (0.47) | TGFBR1PRKD1KDRSYKLRRK2 | |
| SCHEMBL2197036 | 0.80 | ABCG2 (0.54) | TGFBR1PRKD1MEN1NPC1RAB9A | |
| SCHEMBL2202747 | 0.79 | TGFBR1 (0.45) | TGFBR1PRKD1NPC1RAB9AKDR | |
| SCHEMBL4564496 | 0.78 | CSNK2A1 (0.40) | TGFBR1PRKD1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | claimed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | TGFBR1 1039/4885PRKD1 2525/4885MEN1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.